ストックスクリーナーアプリを入手
18.14
6.83%
1.16
アフターアワーズ：
18.17
0.03
+0.17%
前日終値:
$16.98
開ける：
$17.2
24時間の取引高:
173.40K
Relative Volume:
0.74
時価総額：
$823.07M
収益：
-
当期純損益:
$-100.00M
株価収益率:
-7.7123
EPS:
-2.3521
ネットキャッシュフロー:
$-109.23M
1週間 パフォーマンス:
+6.58%
1か月 パフォーマンス:
+2.89%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$17.12
$18.32
1週間の範囲:
$16.30
$18.36
52週間の値動き範囲:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Compare MPLT vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
18.14 | 770.43M | 0 | -100.00M | -109.23M | -2.3521 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-11-21 | 開始されました | Jefferies | Buy |
| 2025-11-21 | 開始されました | Leerink Partners | Outperform |
| 2025-11-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-21 | 開始されました | Stifel | Buy |
Maplight Therapeutics Inc (MPLT) 最新ニュース
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - marketscreener.com
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart.com
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
MapLight2026 Funding Rounds & List of Investors - Tracxn
MapLight $251M IPO Defies Market Slowdown Amid Federal Shutdown - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares - MarketBeat
MapLight Therapeutics director Pavlov buys shares worth $441k By Investing.com - Investing.com Canada
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 By Investing.com - Investing.com South Africa
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 12,116 Shares of Stock - MarketBeat
Forbion discloses 7.1% MapLight Therapeutics (MPLT) ownership stake - Stock Titan
Big Insider Shake-Up at MapLight Therapeutics as Directors Make Opposite Moves - TipRanks
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 6,622 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares - MarketBeat
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com India
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics Inc (MPLT) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):